ArticlePharmaceuticals (Basel, Switzerland)2026
Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control Study.
Guiling Zhou, Nina Dael, Stefan Verweij, Spyros Balafas, Sumaira Mubarik, Jens Bos, Anna Maria Gerdina Pasmooij, Debbie van Baarle, Peter G M Mol, Geertruida H de Bock and 2 more
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Guiling ZhouUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0003-1872-0084 Nina DaelUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
Stefan VerweijUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
Spyros BalafasUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0003-1590-2093 Sumaira MubarikUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0001-6041-1061 Jens BosUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
Anna Maria Gerdina PasmooijDutch Medicines Evaluation Board, 3503 RG Utrecht, The Netherlands.
Debbie van BaarleVirology and Immunology Research Group, Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, The Netherlands.
Peter G M MolDutch Medicines Evaluation Board, 3503 RG Utrecht, The Netherlands.
Geertruida H de BockDepartment of Epidemiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0003-3104-4471 Eelko HakUnit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
Lifelines Corona Research Initiative
Funding
China Scholarship Council 202107720033
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19COVID-19 vaccinationpharmacoepidemiologyrepurposing drugsSARS-CoV-2SARS-CoV-2 varianttest negative case control
Identifiers
PMID42356479
PMCPMC13304682
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390